Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.
Managing RSV
Two Options for RSV Protection in Infants:
There are two safe and effective immunizations to prevent RSV-associated lower respiratory tract infections (LRTIs) in infants (1.) - RSVpreF (Abrysvo) & Nirsevimab (Beyfortus). Most infants will only need to be protected by one of these vaccines.
RSVpreF (Abrysvo) vaccine is approved for maternal adult use during pregnancy to protect infants through 6 months from RSV-associated LRTI. A single dose of the vaccine should be administered from 32 through 36 weeks of gestation.
OR
Nirsevimab (Beyfortus) RSV monoclonal antibody is an approved vaccine for infants (4.). Infants younger than 8 months born during or entering their first RSV season are recommended to get only a single dose (i.e., one shot) (5.) if:
• The patient who was pregnant did not receive RSV vaccination during pregnancy.
• The patient who was pregnant has an unknown RSV vaccination status.
• The infant was born within 14 days of maternal RSV vaccination.
Some infants 8-19 months who have an increased risk for severe RSV disease and are entering their second RSV season are also recommended to get a dose of nirsevimab.
Fact Sheet References
1. Centers for Disease Control and Prevention (CDC). Frequently asked questions about RSVpreF (Abrysvo) vaccine for pregnant people. Accessed May 5, 2024. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html
2. Vaccinate Your Family. Respiratory syncytial virus (RSV). Accessed May 5, 2024. https://vaccinateyourfamily.org/what-is-rsv/
3. CDC. RSV in infants and young children. Accessed May 5, 2024. https://www.cdc.gov/rsv/infants-young-children/index.html
4. CDC. Clinician Outreach and Communication Activity (COCA). Updated guidance for healthcare providers on increased supply of nirsevimab to protect young children from severe respiratory syncytial virus (RSV) during the 2023-2024 respiratory virus season. Accessed May 5, 2024. https://emergency.cdc.gov/ newsletters/coca/2024/010524a.htm
5. CDC. Healthcare providers: RSV prevention information. Accessed May 5, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/child.html
6. CDC. For healthcare providers. Accessed May 5, 2024. https://www.cdc.gov/rsv/hcp/clinical-overview/?CDC_AAref_Val=https://www.cdc.gov/rsv/clinical/index.html
